High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

• Published in: Journal of cellular and molecular medicine Vol. 22; no. 4; pp. 2458 - 2468
• Main Authors: Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2018; John Wiley and Sons Inc
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - pharmacology; ARID1A; Breast cancer; Cell Line, Tumor; Chemotherapy; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; Indoles - pharmacology; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins - genetics; Original; p38 Mitogen-Activated Protein Kinases - genetics; p38MAPK; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Patients; Transcription; Transcription Factors - genetics; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; triple‐negative breast cancer; paclitaxel; triple-negative breast cancer; ARID1A; chemotherapy; p38MAPK
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/jcmm.13551

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT‐rich interaction domain 1A (ARID1A) transcript is up‐regulated in paclitaxel‐sensitive TNBC cells but down‐regulated in paclitaxel‐resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan‐Meier analyses revealed that ARID1A down‐regulation was related to a poorer response to paclitaxel‐based chemotherapy in patients with TNBCs as measured by the recurrence‐free survival probability. The pharmaceutical inhibition with p38MAPK‐specific inhibitor SCIO‐469 revealed that p38MAPK‐related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel‐based chemotherapy.